Quark Pharmaceuticals, Inc. has announced the presentation of positive results from preclinical efficacy studies for its systemically-administered, siRNA compound, AKIi-5, in acute renal failure (ARF) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback